J. Oates

3.8k total citations · 2 hit papers
42 papers, 2.9k citations indexed

About

J. Oates is a scholar working on Oncology, Surgery and Pulmonary and Respiratory Medicine. According to data from OpenAlex, J. Oates has authored 42 papers receiving a total of 2.9k indexed citations (citations by other indexed papers that have themselves been cited), including 31 papers in Oncology, 22 papers in Surgery and 19 papers in Pulmonary and Respiratory Medicine. Recurrent topics in J. Oates's work include Colorectal Cancer Treatments and Studies (22 papers), Gastric Cancer Management and Outcomes (15 papers) and Esophageal Cancer Research and Treatment (10 papers). J. Oates is often cited by papers focused on Colorectal Cancer Treatments and Studies (22 papers), Gastric Cancer Management and Outcomes (15 papers) and Esophageal Cancer Research and Treatment (10 papers). J. Oates collaborates with scholars based in United Kingdom, Spain and Sweden. J. Oates's co-authors include David Cunningham, Alyson Norman, Jervoise Andreyev, Paul A. Clarke, A. Norman, Tamas Hickish, Timothy Iveson, Mark Hill, Andrew Webb and Sheela Rao and has published in prestigious journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and British Journal of Cancer.

In The Last Decade

J. Oates

41 papers receiving 2.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer.

1997 691 citations Andrew Webb, David Cunningham et al. Journal of Clinical Oncology profile →
Kirsten ras Mutations in Patients With Colorectal Cancer: the Multicenter "RASCAL" Study

1998 613 citations David Cunningham, J. Oates et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
J. Oates United Kingdom	23	2.1k	1.7k	1.0k	621	378	42	2.9k
Atsuo Takashima Japan	30	1.7k 0.8×	1.5k 0.9×	923 0.9×	303 0.5×	438 1.2×	222	2.9k
Heung Moon Chang South Korea	27	1.3k 0.6×	1.2k 0.7×	816 0.8×	232 0.4×	581 1.5×	80	2.2k
Masayuki Itabashi Japan	28	832 0.4×	1.3k 0.8×	1.4k 1.4×	412 0.7×	421 1.1×	96	2.7k
J. F. Seitz France	20	1.8k 0.9×	843 0.5×	965 0.9×	1.0k 1.6×	112 0.3×	47	2.6k
Heung-Moon Chang South Korea	25	1.4k 0.7×	908 0.5×	673 0.6×	186 0.3×	222 0.6×	79	2.1k
Radka Obermannová Czechia	18	1.4k 0.7×	1.3k 0.8×	1.1k 1.1×	254 0.4×	106 0.3×	60	2.6k
J. Buesa Spain	26	2.1k 1.0×	2.9k 1.7×	687 0.7×	567 0.9×	561 1.5×	61	3.6k
Hirofumi Yasui Japan	24	1.2k 0.6×	1.5k 0.9×	1.1k 1.1×	155 0.2×	426 1.1×	159	2.4k
Yung‐Jue Bang South Korea	26	1.3k 0.6×	1.1k 0.6×	405 0.4×	353 0.6×	211 0.6×	72	2.0k
Alejandro Majlis Chile	14	1.3k 0.6×	1.9k 1.1×	892 0.9×	287 0.5×	637 1.7×	20	2.4k

Countries citing papers authored by J. Oates

Since Specialization

Citations

This map shows the geographic impact of J. Oates's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J. Oates with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J. Oates more than expected).

Fields of papers citing papers by J. Oates

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J. Oates. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J. Oates. The network helps show where J. Oates may publish in the future.

Co-authorship network of co-authors of J. Oates

This figure shows the co-authorship network connecting the top 25 collaborators of J. Oates. A scholar is included among the top collaborators of J. Oates based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J. Oates. J. Oates is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Sclafani, Francesco, Gina Brown, David Cunningham, et al.. (2017). Comparison between magnetic resonance imaging (MRI) and pathology in the assessment of tumour regression grade (TRG) in rectal cancer (RC). Annals of Oncology. 28. v170–v171. 2 indexed citations

Grenader, Tal, Thomas K. Waddell, Clare Peckitt, et al.. (2016). Prognostic value of neutrophil-to-lymphocyte ratio in advanced oesophago-gastric cancer: exploratory analysis of the REAL-2 trial. Annals of Oncology. 27(4). 687–692. 82 indexed citations

Watkins, David, Naureen Starling, David Cunningham, et al.. (2014). The combination of a chemotherapy doublet (gemcitabine and capecitabine) with a biological doublet (bevacizumab and erlotinib) in patients with advanced pancreatic adenocarcinoma. The results of a phase I/II study. European Journal of Cancer. 50(8). 1422–1429. 23 indexed citations

Sclafani, Francesco, Amitesh Roy, David Cunningham, et al.. (2013). HER2 in high-risk rectal cancer patients treated in EXPERT-C, a randomized phase II trial of neoadjuvant capecitabine and oxaliplatin (CAPOX) and chemoradiotherapy (CRT) with or without cetuximab. Annals of Oncology. 24(12). 3123–3128. 30 indexed citations

Rao, Sheela, Naureen Starling, David Cunningham, et al.. (2010). Matuzumab plus epirubicin, cisplatin and capecitabine (ECX) compared with epirubicin, cisplatin and capecitabine alone as first-line treatment in patients with advanced oesophago-gastric cancer: a randomised, multicentre open-label phase II study. Annals of Oncology. 21(11). 2213–2219. 86 indexed citations

Chau, Ian, A. Norman, David Cunningham, et al.. (2009). The impact of primary tumour origins in patients with advanced oesophageal, oesophago–gastric junction and gastric adenocarcinoma—individual patient data from 1775 patients in four randomised controlled trials. Annals of Oncology. 20(5). 885–891. 40 indexed citations

Léary, Alexandra, L. Assersohn, David Cunningham, et al.. (2008). A phase II trial evaluating capecitabine and irinotecan as second line treatment in patients with oesophago-gastric cancer who have progressed on, or within 3 months of platinum-based chemotherapy. Cancer Chemotherapy and Pharmacology. 64(3). 455–462. 24 indexed citations

Sirohi, Bhawna, David Cunningham, R Powles, et al.. (2008). Long-term outcome of autologous stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma. Annals of Oncology. 19(7). 1312–1319. 88 indexed citations

Chau, Ian, A. Norman, David Cunningham, et al.. (2005). A randomised comparison between 6 months of bolus fluorouracil/leucovorin and 12 weeks of protracted venous infusion fluorouracil as adjuvant treatment in colorectal cancer. Annals of Oncology. 16(4). 549–557. 135 indexed citations

10.

Chau, Ian, A. Norman, David Cunningham, et al.. (2004). Elderly patients with fluoropyrimidine and thymidylate synthase inhibitor-resistant advanced colorectal cancer derive similar benefit without excessive toxicity when treated with irinotecan monotherapy. British Journal of Cancer. 91(8). 1453–1458. 50 indexed citations

11.

Stewart, G., Ian Chau, A. Norman, et al.. (2004). Elderly patients with fluoropyrimidine-resistant advanced colorectal cancer (CRC) derive similar benefit without excessive toxicity when treated with irinotecan monotherapy. Journal of Clinical Oncology. 22(14_suppl). 3622–3622. 3 indexed citations

12.

Saini, Andrea, A. Norman, David Cunningham, et al.. (2003). Twelve weeks of protracted venous infusion of fluorouracil (5-FU) is as effective as 6 months of bolus 5-FU and folinic acid as adjuvant treatment in colorectal cancer. British Journal of Cancer. 88(12). 1859–1865. 61 indexed citations

13.

Rao, Sheela, David Cunningham, Robert C. Hawkins, et al.. (2003). 44 Phase III trial comparing epirubicin, cisplatin and 5-FU (ECF) versus 5FU, etoposide and leucovorin (FELV) in previously untreated patients with advanced biliary cancer. European Journal of Cancer Supplements. 1(5). S17–S17. 2 indexed citations

14.

Chau, Ian, Mark Allen, David Cunningham, et al.. (2003). 51 The value of routine serum carcino-embryonic antigen measurement and computed tomography in the surveillance of patients after adjuvant chemotherapy for colorectal cancer: analysis from a prospective randomised controlled trial. European Journal of Cancer Supplements. 1(5). S20–S20.

15.

Tebbutt, Niall C., A. Norman, David Cunningham, et al.. (2003). Analysis of the time course and prognostic factors determining toxicity due to infused fluorouracil. British Journal of Cancer. 88(10). 1510–1515. 11 indexed citations

16.

Assersohn, L., Gina Brown, David Cunningham, et al.. (2003). Phase II study of irinotecan and 5-fluorouracil/leucovorin in patients with primary refractory or relapsed advanced oesophageal and gastric carcinoma. Annals of Oncology. 15(1). 64–69. 110 indexed citations

17.

Waters, Justin S., Diana Tait, David Cunningham, et al.. (2002). A multicentre phase II trial of primary chemotherapy with cisplatin and protracted venous infusion 5-fluorouracil followed by chemoradiation in patients with carcinoma of the oesophagus. Annals of Oncology. 13(11). 1763–1770. 9 indexed citations

18.

Waters, Justin S., A. Norman, David Cunningham, et al.. (1999). Long-term survival after epirubicin, cisplatin and fluorouracil for gastric cancer: results of a randomized trial. British Journal of Cancer. 80(1-2). 269–272. 221 indexed citations

19.

Ross, Paul J., Andrew Webb, David Cunningham, et al.. (1997). Infusional 5-fluorouracil in the treatment of gastrointestinal cancers: The Royal Marsden Hospital experience. Annals of Oncology. 8(2). 111–115. 6 indexed citations

20.

Rigg, Anne, David Cunningham, M. Gore, et al.. (1997). A phase I/II study of leucovorin, carboplatin and 5-fluorouracil (LCF) in patients with carcinoma of unknown primary site or advanced oesophagogastric/pancreatic adenocarcinomas. British Journal of Cancer. 75(1). 101–105. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact